CAMBRIDGE, Mass., Feb. 16, 2023 /PRNewswire/ -- Today, Convergent Therapeutics Inc., a clinical stage biotechnology company, announced the titles of posters evaluating its lead asset, CONV01-α (225Ac−J591), a prostate-specific membrane antigen (PSMA)-targeted monoclonal antibody linked to Ac-225 (225Ac), that will be presented at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium happening in a hybrid mode at San Francisco, February 16-18.
The complete list of abstract titles can be found here.
Poster presentations will focus on two ongoing clinical studies, a trials-in-progress update from NCT04506567, and a data update from NCT04946370, that are both currently investigating CONV01-α (225Ac−J591) in patients with progressive metastatic castration-resistant prostate cancer (mCRPC) and are led by Principal Investigator Dr. Scott T. Tagawa, Professor of Medicine in Urology at Weill Cornell Medicine.
Convergent Therapeutics, Inc. is a clinical stage biotechnology company focused on developing next-generation radiopharmaceutical therapies for prostate and other cancers. The company's proprietary technology was developed by Dr. Neil Bander, Professor of Urologic Oncology at Weill Cornell Medicine, and licensed to Convergent by Cornell University. CONV01-α, a monoclonal antibody conjugated to actinium-225 (Ac-225), a radioactive alpha particle emitter, was specifically designed to bind to the prostate-specific membrane antigen (PSMA). A key functional feature of CONV01-α is that once bound to PSMA, it becomes internalized, thereby delivering its powerful radioactive payload directly into prostate cancer cells, minimizing damage to surrounding healthy tissue. CONV01-α would be the first radioantibody approved for the use of Ac-225 in cancer treatment. For more information, please visit www.convergentrx.com and follow us on Twitter and LinkedIn.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.